U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07457736) titled 'Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1' on Jan. 29.
Brief Summary: Evaluate [18F]GATT-44 (aka [18F]GAT44), to characterize its pharmacokinetic, metabolic, and in vivo binding profile, and assess the reproducibility of kinetic and binding parameters. Assess specific binding levels of [18F]GATT-44 by conducting a test-block study in humans. Estimate human dosimetry of [18F]GATT-44 by performing whole-body imaging studies.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Adult Participants
Intervention:
DRUG: [ 18F]GATT-44
First in human radiotrac...